Human leucocyte antigen class I-redirected anti-tumour CD4+T cells require a higher T cell receptor binding affinity for optimal activity than CD8+T cells.
CD4+T helper cells are a valuable component of the immune response towards cancer. Unfortunately, natural tumour-specific CD4+T cells occur in low frequency, express relatively low-affinity T cell receptors (TCRs) and show poor reactivity towards cognate antigen. In addition, the lack of human leucocyte antigen (HLA) class II expression on most cancers dictates that these cells are often unable to respond to tumour cells directly. These deficiencies can be overcome by transducing primary CD4+T cells with tumour-specific HLA class I-restricted TCRs prior to adoptive transfer. The lack of help from the co-receptor CD8 glycoprotein in CD4+cells might result in these cells requiring a different optimal TCR binding affinity. Here we compared primary CD4+and CD8+T cells expressing wild-type and a range of affinity-enhanced TCRs specific for the HLA A*0201-restricted NY-ESO-1- and gp100 tumour antigens. Our major findings are: (i) redirected primary CD4+T cells expressing TCRs of sufficiently high affinity exhibit a wide range of effector functions, including cytotoxicity, in response to cognate peptide; and (ii) optimal TCR binding affinity is higher in CD4+T cells than CD8+T cells. These results indicate that the CD4+T cell component of current adoptive therapies using TCRs optimized for CD8+T cells is below par and that there is room for substantial improvement.
Cardiff University School of Medicine, Cardiff, UK.
M P
MP
Tan
Cardiff University School of Medicine, Cardiff, UK.
G M
GM
Dolton
Adaptimmune Ltd, Oxon, UK.
A B
AB
Gerry
Adaptimmune Ltd, Oxon, UK.
J E
JE
Brewer
Adaptimmune Ltd, Oxon, UK.
A D
AD
Bennett
Adaptimmune Ltd, Oxon, UK.
N J
NJ
Pumphrey
Adaptimmune Ltd, Oxon, UK.
B K
BK
Jakobsen
Cardiff University School of Medicine, Cardiff, UK.
A K
AK
Sewell
D000951:Antigens, Neoplasm / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D015316:Genetic Therapy / Q000379:methods*; D015789:HLA-A2 Antigen / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008565:Membrane Proteins / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011485:Protein Binding; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics / Q000378:metabolism*; D019076:Transgenes / Q000235:genetics; D058951:gp100 Melanoma Antigen / Q000378:metabolism
D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen; D008565:Membrane Proteins; D016693:Receptors, Antigen, T-Cell, alpha-beta; D058951:gp100 Melanoma Antigen
CD4+ T cells; MHC class I; TCR affinity; immunotherapy